The attached table shows the novel drugs marketed in 2018.


Order No. | Trade name | Common name | Approval date | Mechanism | Indication | Company |
56 | Motegrity | prucalopride | 2018-12-14 | 5-HT4 receptor agonist | Chronic idiopathic constipation | J & J/Shire |
55 | Xospata | gilteritinib | 2018-11-28 | Axl/Flt3 inhibitor | r/r-AML | Astellas Pharma |
54 | Firdapse | amifampridine | 2018-11-28 | Potassium channel blocker | Lambert-Eaton myasthenic syndrome | Catalyst Pharmaceuticals |
53 | Vitrakvi | larotrectinib | 2018-11-26 | TRK inhibitor | Advanced solid tumors harboring an NTRK gene fusion | Loxo Oncology |
52 | Daurismo | glasdegib | 2018-11-21 | SMO receptor agonist | Acute leukemia | Pfizer |
51 | Gamifant | emapalumab | 2018-11-20 | INFγ mAb | Primary hemophagocytic lymphohistiocytosis | Novimmune sobi |
50 | Aemcolo | rifamycin | 2018-11-16 | Rifamycin | Travelers’ diarrhea | Cosmo Pharmaceuticals |
49 | Yupelri | Read More
Related News
InnoCare Announces FDA Approval of Clinical Trial for BCL2 Inhibitor Mesutoclax in AML and MDS
PharmaSources July 14, 2025 You may like
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Most popular
The Rise of Biosimilars: Regulatory Pathways and Market Outlook
Nurah Ekhlaque
Sep 19, 2025
Methodology Validation in Chinese Pharmacopoeia 2025: How to Report Accuracy and Precision
Xing Xing
Sep 12, 2025
Digitalization in Procurement: From AI Forecasting to Blockchain Traceability
Saher Haider
Sep 19, 2025
|










(All Rights Reserved)